Active and early treatment of autoimmune myasthenia ensures a better long-term outcome

Japanese researchers retrospectively analysed the treatment regimens of 1066 patients diagnosed with generalised myasthenia gravis.

  • Early cycles of fast-acting treatment (EFT) included plasmapheresis (EP), intravenous immunoglobulin (IVIG) injections and bolus methylprednisolone.
  • Their efficacy was judged on their ability to induce complete remission or treatment with corticosteroids of less than 5 mg daily.
  • Comparing data from 350 patients who received ETFs with 350 patients who did not receive ETFs, the result was strongly in favour of early therapy.

The authors also report the benefit of adjuvant treatment with calcineurin inhibitors.


Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. Uzawa A, Suzuki S, Kuwabara S et al. J Neurol Neurosurg Psychiatry. 2023 Jan 24:jnnp-2022-330519.